Institution
Chinese PLA General Hospital
Healthcare•Beijing, China•
About: Chinese PLA General Hospital is a healthcare organization based out in Beijing, China. It is known for research contribution in the topics: Medicine & Population. The organization has 18037 authors who have published 12349 publications receiving 184803 citations. The organization is also known as: 301 Military Hospital.
Topics: Medicine, Population, Cancer, Transplantation, Apoptosis
Papers published on a yearly basis
Papers
More filters
••
University of Copenhagen1, Northeast Ohio Medical University2, University of Bern3, Sunnybrook Research Institute4, Policlinico Umberto I5, University of São Paulo6, Jaslok Hospital7, Chung-Ang University8, Ludwig Maximilian University of Munich9, Huazhong University of Science and Technology10, Fudan University11, University of Verona12, University of Michigan13, University of Bergen14, Zhejiang University15, University of California, San Diego16, Kindai University17, Université Paris-Saclay18, Samsung Medical Center19, New Generation University College20, Chinese PLA General Hospital21, Imperial College London22, Thomas Jefferson University Hospital23, University of Pavia24, Paris Descartes University25, International University of Health and Welfare26, University of Barcelona27, University of Bologna28, University of Medicine and Pharmacy of Craiova29, King's College London30, Humanitas University31, Sun Yat-sen University32
TL;DR: The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast-enhanced ultrasound, first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology, intended to create standard protocols for the use and administration of UCAs in liver applications on an international basis to improve the management of patients.
Abstract: The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast-enhanced ultrasound, first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology. The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications. The 2012 guideline requires updating as, previously, the differences in the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including U.S. Food and Drug Administration approval and the extensive Asian experience, to produce a truly international perspective. These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCAs) and are intended to create standard protocols for the use and administration of UCAs in liver applications on an international basis to improve the management of patients.
227 citations
••
TL;DR: Early studies are reviewed, strategies to improve the therapeutic potential and safety are considered, and the challenges and future prospects for CAR T-cells in cancer therapy are discussed.
Abstract: The genetic modification and characterization of T-cells with chimeric antigen receptors (CARs) allow functionally distinct T-cell subsets to recognize specific tumor cells. The incorporation of costimulatory molecules or cytokines can enable engineered T-cells to eliminate tumor cells. CARs are generated by fusing the antigen-binding region of a monoclonal antibody (mAb) or other ligand to membrane-spanning and intracellular-signaling domains. They have recently shown clinical benefit in patients treated with CD19-directed autologous T-cells. Recent successes suggest that the modification of T-cells with CARs could be a powerful approach for developing safe and effective cancer therapeutics. Here, we briefly review early studies, consider strategies to improve the therapeutic potential and safety, and discuss the challenges and future prospects for CAR T-cells in cancer therapy.
226 citations
••
TL;DR: An assay that thermophoretically profiles surface proteins from serum extracellular vesicles labelled with a panel of fluorescent aptamers detects and classifies patients according to cancer type and cancer stage, and if validated in larger cohorts may facilitate cancer screening, classification and monitoring.
Abstract: Non-invasive assays for early cancer screening are hampered by challenges in the isolation and profiling of circulating biomarkers. Here, we show that surface proteins from serum extracellular vesicles labelled with a panel of seven fluorescent aptamers can be profiled, via thermophoretic enrichment and linear discriminant analysis, for cancer detection and classification. In a cohort of 102 patients, including 6 cancer types at stages I–IV, the assay detected stage I cancers with 95% sensitivity (95% confidence interval (CI): 74–100%) and 100% specificity (95% CI: 80–100%), and classified the cancer type with an overall accuracy of 68% (95% CI: 59–77%). For patients who underwent prostate biopsies, the assay was superior to the analysis of prostate-specific antigen levels (area under the curve: 0.94 versus 0.68; 33 patients) for the discrimination of prostate cancer and benign prostate enlargement, and also in the assessment of biochemical cancer recurrence after radical prostatectomy. The assay is inexpensive, fast, and requires small serum volumes (<1 µl), and if validated in larger cohorts may facilitate cancer screening, classification and monitoring. An assay that thermophoretically profiles surface proteins from serum extracellular vesicles labelled with a panel of fluorescent aptamers detects and classifies patients according to cancer type and cancer stage.
226 citations
••
Capital Medical University1, Jinan University2, Chinese PLA General Hospital3, Third Military Medical University4, Nanjing Medical University5, Shenzhen University6, Zhejiang University7, Southern Medical University8, Tongji University9, Peking University10, Zhengzhou University11, Nanjing University12
TL;DR: To report the performance of massively parallel sequencing (MPS) based prenatal noninvasive fetal trisomy test based on cell‐free DNA sequencing from maternal plasma in a routine clinical setting in China.
Abstract: Objective To report the performance of massively parallel sequencing (MPS) based prenatal noninvasive fetal trisomy test based on cell-free DNA sequencing from maternal plasma in a routine clinical setting in China. Method The MPS-based test was offered as a prenatal screening test for trisomies 21 and 18 to pregnant women in 49 medical centers over 2years. A total of 11263 participants were recruited and the MPS-based test was performed in 11105 pregnancies. Fetal outcome data were obtained after the expected date of confinement. Results One hundred ninety cases were classified as positive, including 143 cases of trisomy 21 and 47 cases of trisomy 18. With the karyotyping results and the feed back of fetal outcome data, we observed one false positive case of trisomy 21, one false positive case of trisomy 18 and no false negative cases, indicating 100% sensitivity and 99.96% specificity for the detection of trisomies 21 and 18. Conclusion Our large-scale multicenter study proved that the MPS-based test is of high sensitivity and specificity in detecting fetal trisomies 21 and 18. The introduction of this screening test into a routine clinical setting could avoid about 98% of invasive prenatal diagnostic procedures. © 2012 John Wiley & Sons, Ltd. Supporting information may be found in the online version of this article.
226 citations
••
TL;DR: The signaling molecule effect and the biomechanics effect of cartilage ECM on chondrogenesis are emphasized and integrin-mediated signaling via cell-matrix interaction is emphasized.
Abstract: Cartilage extracellular matrix (ECM) is composed primarily of the network type II collagen (COLII) and an interlocking mesh of fibrous proteins and proteoglycans (PGs), hyaluronic acid (HA), and chondroitin sulfate (CS). Articular cartilage ECM plays a crucial role in regulating chondrocyte metabolism and functions, such as organized cytoskeleton through integrin-mediated signaling via cell-matrix interaction. Cell signaling through integrins regulates several chondrocyte functions, including differentiation, metabolism, matrix remodeling, responses to mechanical stimulation, and cell survival. The major signaling pathways that regulate chondrogenesis have been identified as wnt signal, nitric oxide (NO) signal, protein kinase C (PKC), and retinoic acid (RA) signal. Integrins are a large family of molecules that are central regulators in multicellular biology. They orchestrate cell-cell and cell-matrix adhesive interactions from embryonic development to mature tissue function. In this review, we emphasize the signaling molecule effect and the biomechanics effect of cartilage ECM on chondrogenesis.
226 citations
Authors
Showing all 18235 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jie Zhang | 178 | 4857 | 221720 |
Gregory Y.H. Lip | 169 | 3159 | 171742 |
Chao Zhang | 127 | 3119 | 84711 |
Hong Wang | 110 | 1633 | 51811 |
Shuji Ogino | 106 | 549 | 43073 |
Li Chen | 105 | 1732 | 55996 |
Jing Wang | 97 | 1123 | 53714 |
Wei Wang | 95 | 3544 | 59660 |
Zhiguo Yuan | 93 | 633 | 28645 |
Tai Hing Lam | 93 | 1168 | 51646 |
Christopher P. Crum | 87 | 412 | 32399 |
Guozhen Shen | 84 | 422 | 23992 |
Jing-Feng Li | 81 | 507 | 23434 |
Zongjin Li | 80 | 630 | 22103 |
Wan Yee Lau | 76 | 463 | 21257 |